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a  b  s  t  r  a  c  t
Amelanotic  melanoma  of the  oral  mucosa  is  extremely  rare.  We  describe  herein  our experience  of  amelan-
otic melanoma  arising  in  the  mandibular  mucosa.  An  85-year-old  woman  was  referred  to  our  clinic  withccepted 2 June 2011
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swelling  of  the  left  lower  gingival  mucosa.  The  histopathological  diagnosis  was  amelanotic  melanoma,
as  determined  by  immunohistochemical  examination.  The  tumor  cells  were  positive  for  S-100,  Melan-A,
HMB-45,  and  vimentin.  The  patient  declined  surgical  treatment,  so  she  received  irradiation  therapy.  At
a  total  dose  of 10  Gy,  the patient  exhibited  lassitude,  so  we  terminated  radiotherapy.  Bleeding  from  the
tumor  persisted,  and  the  patient  developed  anemia  and  hypouresis.  She  also  contracted  pneumonia.  The
patient’s general  condition  worsened,  and  she  died.
 Japan© 2012
. Introduction
Over 90% of all melanomas occur on the skin surfaces, and
lightly over 1% of melanomas arise from mucosal surfaces [1].  The
ost common site for mucosal melanoma is the head and neck
egion (55%), followed by the anal/rectal region (24%), female geni-
al tract (18%), and urinary tract (3%) [1]. Oral melanomas comprise
0% of head and neck melanomas, and the most frequent site of oral
elanoma is the palate, followed by maxillary gingiva. In a previous
tudy, mandibular gingival melanomas comprised 7% of 703 cases
f melanoma [1].  Whereas pigmented melanoma is usually easy to
iagnose clinically, amelanotic melanoma (AM), which lacks pig-
entation, often requires biopsy for correct clinical diagnosis [2].
ere, we report a case of AM arising in the mandibular mucosa.
. Case report
An 85-year-old woman was referred to our clinic by her den-
ist because of swelling of the left lower gingival mucosa. The
atient’s medical history was not contributory. She had only one
olar tooth in the mandible, and she had not used her full and par-
ial dentures for about 2 years. About 2 weeks before visiting our
linic, she noticed swelling of the left lower alveolar ridge. Since
he swelling increased gradually, she consulted her dentist, and
as then referred to our clinic. Her general condition was good.
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Extraoral examination did not demonstrate any remarkable fea-
tures. There were 3 palpable cervical and submandibular lymph
nodes on the left side. Intraoral examination demonstrated elas-
tic hard swelling that measured 48 × 27 × 18 mm,  extending from
the edentulous mucosa to the buccal mucosa in the left premolar
and molar region (Fig. 1). The surface of the lesion was  rough, with
ill-deﬁned borders, and there was an induration around the tumor.
Panoramic radiography did not show any conspicuous masses.
Computed tomographic (CT) scan of the head and neck demon-
strated a mass invading the mylohyoid muscle in the left
mandibular and buccal region. Cortical bone resorption was
observed in the left lower molar region and ramus of the mandible.
The resorption of the mandibular body was not remarkable.
Enhanced CT demonstrated uptake in the upper internal jugu-
lar nodes on the left side (Fig. 2). Many lymph nodes exhibited
rim enhancement. Radioisotope scintigraphy of bone and gallium
demonstrated hot areas only in the left mandible and neck lym-
phadenopathy. There were no cutaneous lesions. After admission,
an incisional biopsy was  performed under local anesthesia. On clin-
ical examination, there was  no evidence of pigmentation in the
specimen. There was  no evidence of metastatic lesions on chest or
abdominal CT. The histopathological diagnosis was AM. The patient
declined surgical treatment, so we  performed Linac X-ray radio-
therapy (2 Gy per day) to treat the oral lesion and metastatic lymph
nodes. At a total dose of 10 Gy, the patient exhibited lassitude, so
we terminated radiotherapy. Bleeding from the tumor persisted,
and the patient developed anemia and hypouresis. She also con-
tracted pneumonia. Although we  attempted physical treatment,
the patient’s general condition worsened, and she died.
evier Ltd. All rights reserved.
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cells. Furthermore, the tumor in our case did not invade the bone
F
eFig. 1. View of swelling mass of left mandibular molar region.
. Pathological ﬁndings
Microscopically, the specimen exhibited diffuse proliferation
f large round cells with bizarre nuclei and plump eosinophilic
ytoplasm below the ulcerated surface (Fig. 3A). Nuclei were
rregular-shaped and included small distinct nucleoli. Many mitotic
gures were observed and multinucleate cells were scattered
hroughout the specimen. Melanin granules were not detected
n the cytoplasm in hematoxylin & eosin (H–E) staining and
ontana–Masson staining (Fig. 3B). Immunohistochemically the
umor cells were positive for S-100 (Fig. 3C), Melan-A (Fig. 3D),
MB-45, and vimentin, but were negative for keratin, EMA, LCA,
CHL-1, CD20, and CD30. Ki-67 labeling index using MIB-1 anti-
ody was 54.3%. On the basis of the histopathological ﬁndings, the
esion was diagnosed as AM.
. DiscussionAM is an extremely rare lesion, comprising 2–8% of all
elanomas [2]. Only 33 cases of oral AM have been reported in
he English and Japanese literature [2–21], excluding the present
ig. 2. (A) Computed tomography (CT) demonstrating mass invading bone and mylohyoi
nhancement in many lymph nodes.ternational 8 (2011) 60– 63 61
case. The sites in those cases were palatal (n = 17), maxillary gingiva
(n = 13), upper lip mucosa (n = 1), and mandibular gingiva (n = 2).
It is difﬁcult to distinguish AM from other malignant lesions such
as undifferentiated carcinoma, ﬁbrosarcoma, or malignant lym-
phoma. We  suspected a poorly differentiated carcinoma because
we observed numerous atypical cells, nuclear atypia, and atypical
mitosis. Despite the characteristic observation of prominent nucle-
ori, cytoplasmic vascularization, and intranuclear cytoplasmic
inclusion, it was  difﬁcult to distinguish our case from other malig-
nant tumors such as poorly differentiated carcinoma. Therefore,
we suggest that an additional immunohistochemical examination
is crucial to differential diagnosis.
Immunohistochemistry is generally used for differential diagno-
sis of AM.  The standard melanoma immunohistochemical antigens
include S-100 protein (a fairly sensitive but not overly speciﬁc anti-
gen), HMB-45 (a marker of premelanosomes that stains melanoma
cells and melanocytes in some nevi) [22], and Melan-A/MART-
1 (an antigen on melanoma cells by cytotoxic T-lymphocytes)
[23,24]. Gibson and Goellner [25] reported that 13 of 15 cases
of AM were positive for S-100 protein. Adenocarcinomas such as
breast or eccrine tumors and clear cell sarcoma can resemble AM
morphologically, and also stain positively for S-100 protein. Wick
et al. [26] performed S-100 immunohistochemical staining of vari-
ous tumors, obtaining the following results: melanomas (n = 67),
100% positive; eccrine carcinomas, 43%; metastatic visceral car-
cinomas, 25%; malignant schwannomas 100%; leiomyosarcomas,
80%. In contrast, although 62 (92%) of those 67 melanomas were
positive for HMB-45, all other neoplasms they tested were neg-
ative for HMB-45. Melan-A is useful in the differential diagnosis
of melanocytic tumors, since it is more sensitive than HMB-45. In
the present case, because the specimen was  positive for S-100 pro-
tein, HMB-45, and Melan-A, but negative for lymphoma-associated
antigens, we diagnosed the tumor as AM.  It is important to deter-
mine the existence of melanocytes in the specimen for differential
diagnosis with melanoma. Detection of melanocytes is easy when
they contain brown melanin granules. But AM cannot be diagnosed
only by H–E stained specimen. The immunohistochemical exami-
nation using these antibodies is very helpful to identify the AMremarkably, although the tumor was  quite big and many metastatic
lymph nodes were detected. General examination did not detect
any extraoral lesions.
d muscle in left lower molar region of the mandible. (B) Enhanced CT showing rim
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Fig. 3. (A) Photomicrograph of amelanotic melanoma shows diffuse proliferation of large round cells with atypical nuclei and eosinophilic cytoplasm. [Hemotoxylin & eosin
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xpressions are found in almost all tumor cells. ×40. (E) Immunohistochemistry for
Mucosal AM is generally treated according to the guidelines
or pigmented melanomas [22]. Radical surgery is the most com-
on  treatment for oral melanoma [27]. Furthermore, adjuvant
ostoperative radiotherapy is standard treatment for oral mucosal
elanoma as it decreases the incidence of local recurrence after
urgical resection, and some reports indicate that radiation ther-
py is effective for melanoma of the head and neck region [9,28].
e  used radiation therapy in a palliative role, consulting with the
atient and her family.
Adjuvant immunochemotherapy may  be associated with
urgery. Dacarbazine-DTIC and interferon-alpha-2b have been
escribed as chemotherapical and immunotherapical treatments,
ssociated in different combinations to Bacille de Calmette et
uérin (GCG) and recombinant interleukin-2 [29]. Studies have
valuated the systemic immunochemotherapy used in metastatic
elanoma of cutaneous sites [30,31]. These studies have shownhat immunochemotherapy has highest response rates among sys-
emic therapy regimens, reaching up to 40–60% [30,31].
In general, the prognosis for patients with oral malignant
elanoma is poorer than that of patients with cutaneous lesions.positive cell. ×40. (D) Immunohistochemistry for S-100. Cytoplasmic and nuclear
n-A. Granular localization is observed in the cytoplasm of the tumor cells. ×40.
Two factors have been found to be associated with the progno-
sis of the disease: tumor size and evidence of metastatic disease.
Graniel et al. [27] reported that, in their series of oral malig-
nant melanomas, the only patients who  survived free of disease
for longer than 5 years were those with a small tumor (<4 cm),
without evidence of lymph node metastasis, had complete tumor
excision, and were treated with radical surgical resection plus
adjuvant radiotherapy. In the present case, many lymph node
metastases were observed, and tumor of the oral mucosa grad-
ually increased in size. Radiation therapy was  not effective in
treating the present case, and the patient unfortunately died of
cachexia.
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